Becton Dickinson to acquire Bard for $23.5bn
Becton Dickinson & Co. agreed to acquire CR Bard Inc. (medtech focused on vascular, urology, and oncology) for $317 per common share (27% premium), or $23.5bn in cash and stock including net debt.
- Medical Devices
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Sealants
Diagnostic Imaging Equipment & Supplies
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.